Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) Infections

Watkins, Richard R.

doi:10.1093/cid/ciad093

Cited by 11 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…used in clinical practice can inhibit β-lactamase produced by bacteria. However, how to release these inhibitors together with antibiotics to the site of infection is still a challenge (Watkins & Bonomo, 2023).…”

Section: Inactivating Enzymementioning

confidence: 99%

Nanotechnology‐driven strategies to enhance the treatment of drug‐resistant bacterial infections

Zhang,

Liu,

Guo

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The misuse of antibiotics has led to increased bacterial resistance, posing a global public health crisis and seriously endangering lives. Currently, antibiotic therapy remains the most common approach for treating bacterial infections, but its effectiveness against multidrug‐resistant bacteria is diminishing due to the slow development of new antibiotics and the increase of bacterial drug resistance. Consequently, developing new a\ntimicrobial strategies and improving antibiotic efficacy to combat bacterial infection has become an urgent priority. The emergence of nanotechnology has revolutionized the traditional antibiotic treatment, presenting new opportunities for refractory bacterial infection. Here we comprehensively review the research progress in nanotechnology‐based antimicrobial drug delivery and highlight diverse platforms designed to target different bacterial resistance mechanisms. We also outline the use of nanotechnology in combining antibiotic therapy with other therapeutic modalities to enhance the therapeutic effectiveness of drug‐resistant bacterial infections. These innovative therapeutic strategies have the potential to enhance bacterial susceptibility and overcome bacterial resistance. Finally, the challenges and prospects for the application of nanomaterial‐based antimicrobial strategies in combating bacterial resistance are discussed.This article is categorized under: Biology‐Inspired Nanomaterials > Nucleic Acid‐Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease

show abstract

Section: Inactivating Enzymementioning

confidence: 99%

Nanotechnology‐driven strategies to enhance the treatment of drug‐resistant bacterial infections

Zhang,

Liu,

Guo

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…A. baumannii represents an additional concerning carbapenem-resistant pathogen in NP [ 54 , 55 ]. Of note, carbapenem resistance among A. baumannii continues to rise at an alarming rate.…”

Section: Treatmentmentioning

confidence: 99%

“…Unfortunately, this meta-analysis relied on few RCTs to support its conclusions. Although typically viewed simply as a β-lactamase inhibitor, sulbactam also exhibits direct antibacterial activity against A. baumannii through the saturation of essential penicillin binding proteins [ 44 , 55 ]. Other therapeutic options include minocycline, tigecycline, polymyxin B, colistin, extended-infusion meropenem, and cefiderocol.…”

Section: Treatmentmentioning

confidence: 99%

“…Durlobactam is a novel broad-spectrum diazabicyclooctane non-β-lactam β-lactamase inhibitor that is active against Ambler class A, C, and D β-lactamases. It has been shown to restore the activity of sulbactam against multidrug resistant A baumannii in in vitro studies [ 55 ]. A recently reported clinical trial assessed the efficacy and safety of sulbactam–durlobactam as compared to colistin in patients with CRAB infections [ 59 ].…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More Challenges

Masri,

Busack,

Shorr

2024

Pathogens

View full text Add to dashboard Cite

Nosocomial pneumonia (NP) represents a leading nosocomial infection and results in substantial morbidity and cost. Over the last several years, the evidence has evolved which directs our approach to NP. Specifically, the definition of NP and classification of its various subtypes has expanded to capture nuances among various phenotypes of this syndrome. For example, segregating those with hospital-acquired pneumonia (HAP) based on whether they subsequently require mechanical ventilation has been shown to be important. Likewise, newer data indicate the true economic cost of NP and underscore the diverse range of pathogens that can cause NP. Moreover, multidrug-resistant (MDR) bacteria have become a major threat in NP. Fortunately, newer simple preventive strategies have been tested and found to be effective at reducing the incidence of NP. Should prevention fail, a range of new antibiotics have been formally studied in NP and found to be effective. Some of these novel agents have relatively broad ranges of activity and are in vitro active against select MDR organisms. Others, however, are narrower in spectrum and directed against specific problem bacteria. In short, the literature in the field of NP has progressed rapidly, and clinicians require a clear appreciation of these changes so as to improve patient outcomes.

show abstract

Sulbactam/Durlobactam: First Approval

Keam

2023

Drugs

View full text Add to dashboard Cite

A co-packaged product containing a β-lactam antibacterial and β-lactamase inhibitor (sulbactam) and a βlactamase inhibitor (durlobactam) that has been being developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumanniicalcoaceticus complex (ABC) • Received its first approval on 23 May 2023 in the USA • Approved for use in patients 18 years of age and older for the treatment of HABP/VABP caused by susceptible isolates of ABC This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online.

show abstract

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Cited by 11 publications

References 24 publications

Nanotechnology‐driven strategies to enhance the treatment of drug‐resistant bacterial infections

Nanotechnology‐driven strategies to enhance the treatment of drug‐resistant bacterial infections

Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More Challenges

Sulbactam/Durlobactam: First Approval

Contact Info

Product

Resources

About